HP
HPHA.XETRA Heidelberg Pharma AG
- Market cap
- EUR 95.9M
- P/E
- -
- P/B
- 7.83x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Aug 2026.
Is HPHA.XETRA undervalued?
Graham numberThe Graham number of Heidelberg Pharma AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Heidelberg Pharma AG fundamental analysis
No fundamental analysis for Heidelberg Pharma AG yet.
Heidelberg Pharma AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Heidelberg Pharma AG
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally. The company's lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It also develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the trea…
Full company profileHeidelberg Pharma AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Aug 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Heidelberg Pharma AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.36M | 1.90M | 3.67M | 7.31M | 8.49M | 2.90M | 18.5M | 9.86M | 6.85M | 1.46M | 12.4M |
| Gross Profit | 553K | 943K | 1.46M | 3.57M | 2.89M | -1.81M | 13.8M | 6.61M | 5.07M | -1.19M | 10.1M |
| Operating Income | -6.36M | -10.8M | -11.7M | -10.4M | -18.6M | -25.1M | -17.2M | -21.2M | -20.7M | -47.4M | -14.0M |
| EBITDA | -6.08M | -10.3M | -11.7M | -9.60M | -17.6M | -24.3M | -16.2M | -18.7M | -14.5M | -44.6M | -11.0M |
| Net Income | -6.39M | -11.0M | -11.7M | -10.1M | -18.4M | -26.1M | -19.7M | -20.3M | -19.4M | -42.3M | -11.6M |
| EPS | -0.22 | -0.76 | -0.41 | -0.36 | -0.61 | -0.80 | -0.53 | -0.44 | -0.42 | -0.91 | -0.26 |
| Balance Sheet | |||||||||||
| Total Assets | 15.2M | 41.5M | 31.2M | 23.0M | 19.6M | 21.7M | 101M | 70.4M | 60.7M | 38.1M | 42.8M |
| Total Liabilities | 5.49M | 4.47M | 5.31M | 6.70M | 6.73M | 15.0M | 33.9M | 21.0M | 29.9M | 49.1M | 62.1M |
| Shareholders' Equity | 9.76M | 37.0M | 25.9M | 16.3M | 12.9M | 6.70M | 66.6M | 49.3M | 30.9M | -10.9M | -19.3M |
| Cash & Short-term Investments | 4.57M | 30.4M | 19.4M | 9.88M | 4.98M | 6.14M | 81.3M | 43.4M | 29.4M | 15.0M | 19.8M |
| Total Debt | 3.75M | - | - | - | 203K | 10.6M | 16.0M | 5.83M | 22.0M | 1.16M | 299K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -6.53M | -7.94M | -9.98M | -8.56M | -17.9M | -26.6M | -8.86M | -33.7M | -29.6M | -31.6M | -16.5M |
| Capital Expenditure | 538K | 416K | 1.00M | 963K | 1.43M | 1.39M | 613K | 960K | 456K | 129K | 19.7K |
| Free Cash Flow | -7.07M | -8.36M | -11.0M | -9.52M | -19.3M | -28.0M | -9.48M | -34.6M | -30.0M | -31.7M | -16.5M |
| Ratios | |||||||||||
| ROE | -65.5% | -29.6% | -45.1% | -62.3% | -142.7% | -390.2% | -29.6% | -41.2% | -62.8% | - | - |
| ROA | -41.9% | -26.4% | -37.4% | -44.1% | -93.7% | -120.3% | -19.6% | -28.9% | -31.9% | -110.9% | -27.0% |
| Net Profit Margin | -469.1% | -577.4% | -318.2% | -138.8% | -216.5% | -900.6% | -106.4% | -206.4% | -283.0% | -2,901.1% | -93.3% |
| Debt to Equity | 0.38x | - | - | - | 0.02x | 1.59x | 0.24x | 0.12x | 0.71x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Heidelberg Pharma AG dividends
Heidelberg Pharma AG has not paid dividends in the last 9 fiscal years.
Last stock split: 1:4 on Jul 18, 2014.
Who owns Heidelberg Pharma AG
- Insiders 79.00%
- Institutions 1.73%
- Public & others 19.27%
- Shares outstanding 46.8M
- Free float 9.25M
Heidelberg Pharma AG company profile
- Company name
- Heidelberg Pharma AG
- Ticker
- HPHA.XETRA
- ISIN
- DE000A11QVV0
- Exchange
- XETRA Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 33
- Fiscal year end
- November
- Address
- Gregor-Mendel-Strasse 22, Ladenburg, Germany, 68526
- Phone
- 49 6203 1009 0
- Website
- heidelberg-pharma.com
About Heidelberg Pharma AG
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally. The company's lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It also develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors; HDP-201 for the treatment of colorectal cancer; and TAK-ATAC for the treatment of oncology. In addition, the company develops TLX250-CDx, a diagnostic antibody for kidney cancer that is in Phase III trials, as well as for the treatment of bladder cancer. Further, it develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for the treatment of kidney cancer; and RHB-107, an orally serine protease inhibitor that is in Phase II study to treat COVID-19. The company has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia, and Antibody Drug Conjugates (ADCs). The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is headquartered in Ladenburg, Germany.
Heidelberg Pharma AG management
5- Dr. Dongzhou Liu Ph.D.CEO & Chairman of Executive Management Board
- Mr. Peter WillingerChief Financial Officer
- Dr. Jorg KemkowskiChief Operating Officer
- Sylvia WimmerSenior Director of Corporate Communications
- Dr. George Octavian BadescuChief Business Officer